Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.

European journal of cancer (Oxford, England : 1990) - 25 Jun 2026

Ishikawa Shiori, Ouchi Kota, Wakayama Shonosuke, Oyamada Shunsuke, Iwasaki Tomoyuki, Numakura Ryunosuke, Yoshida Yuya, Taniguchi Sakura, Kasahara Yuki, Komine Keigo, Saijo Ken, Shirota Hidekazu, Kawakami Hisato

Abstract excerpt

BACKGROUND: Biliary tract cancer (BTC) is a biologically heterogeneous malignancy with a poor prognosis. Although the combination of an immune checkpoint inhibitor (ICI) with gemcitabine plus cisplatin (GC) is now a standard first-line therapy for advanced BTC, the genomic determinants of treatment outcome have remained unclear. METHODS: We investigated the relation between genomic alterations and overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Immune Checkpoint Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42190397
DOI: 10.1016/j.ejca.2026.116826

Genes

GC
KRAS
TP53
BTC
CDKN2A
CAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.PMID 42190397Read ↗

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer.Semantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer.Semantic proximity Read ↗

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Semantic proximity Read ↗

Translating cancer genomics for precision oncology in biliary tract cancers.Semantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune SignaturesSemantic proximity Read ↗

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancerSemantic proximity Read ↗

Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer.Semantic proximity Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.